Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2026)

Aquestive Therapeutics' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 4.2% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 4.2% YoY), while the FY2025 annual figure was $1.1 million, down 94.81% from the prior year.
• Current Deferred Revenue was $1.1 million for Q1 2026 at Aquestive Therapeutics, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $37.1 million in Q2 2023 to a low of $1.0 million in Q2 2024.
• Historically, Current Deferred Revenue has averaged $10.4 million across 5 years, with a median of $1.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue surged 2250.31% in 2022, then slumped 97.18% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $1.5 million in 2022, then grew by 2.51% to $1.6 million in 2023, then soared by 1257.38% to $21.1 million in 2024, then tumbled by 94.81% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.